Go Pro
NYSEAMERICAN:ZOM

Zomedica (ZOM) Stock Price, News & Analysis

Zomedica logo

About Zomedica Stock (NYSEAMERICAN:ZOM)

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
790,936 shs
Average Volume
4.72 million shs
Market Capitalization
$95.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Zomedica Corp. is a veterinary health company focused on developing and commercializing diagnostic and therapeutic products for companion animals, primarily dogs and cats. Its offerings are intended to support veterinary professionals in diagnosing medical conditions and providing treatments in clinical settings.

The company’s product portfolio includes the TRUFORMA diagnostic platform, which is designed to perform certain point-of-care blood tests for veterinary applications, including tests related to thyroid and adrenal conditions. Zomedica also offers therapeutic technologies through its PulseVet business, which provides shock-wave therapy systems used by veterinarians in areas such as soft-tissue and orthopedic care.

Zomedica has expanded its business through acquisitions and product development in the veterinary diagnostics, medical devices and animal wellness markets. The company serves veterinary practices and animal-health professionals, with its primary commercial focus in the United States. Its products are marketed to support companion-animal care rather than human medical applications.

AI Generated. May Contain Errors.

Receive ZOM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zomedica and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ZOM Stock News Headlines

CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel
Zomedica Corp. (ZOMDF) Q2 2026 Earnings Call Transcript
ZOMEDICA CORP
See More Headlines

ZOM Stock Analysis - Frequently Asked Questions

Zomedica Corp. (NYSEAMERICAN:ZOM) announced its quarterly earnings data on Thursday, November, 7th. The company reported ($0.01) earnings per share for the quarter. The company had revenue of $7 million for the quarter. Zomedica had a negative net margin of 232.88% and a negative trailing twelve-month return on equity of 12.47%.
Read the conference call transcript
.

Shares of ZOM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zomedica investors own include Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT), Phunware (PHUN) and

Company Calendar

Last Earnings
11/07/2024
Today
9/29/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NYSEAMERICAN:ZOM
CIK
1684144
Fax
N/A
Employees
50
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.06)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$34.53 million
Net Margins
-232.88%
Pretax Margin
-232.24%
Return on Equity
-12.47%
Return on Assets
-11.84%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.82
Quick Ratio
10.15

Sales & Book Value

Annual Sales
$25.19 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.24 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
979,950,000
Free Float
938,890,000
Market Cap
$95.35 million
Optionable
Not Optionable
Beta
1.03
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NYSEAMERICAN:ZOM) was last updated on 9/29/2026 by MarketBeat.com Staff.
From Our Partners